350 related articles for article (PubMed ID: 24376239)
1. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
Yang JS; Lee C; Cho M; Kim H; Kim JH; Choi S; Oh SJ; Kang JS; Jeong JH; Kim HJ; Han G
J Med Chem; 2015 Apr; 58(8):3512-21. PubMed ID: 25811792
[TBL] [Abstract][Full Text] [Related]
3. Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
Song D; Lee C; Kook YJ; Oh SJ; Kang JS; Kim HJ; Han G
Eur J Med Chem; 2017 Jan; 126():997-1010. PubMed ID: 28011426
[TBL] [Abstract][Full Text] [Related]
4. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II.
Lee C; Choi E; Cho M; Lee B; Oh SJ; Park SK; Lee K; Kim HM; Han G
Bioorg Med Chem Lett; 2012 Jun; 22(12):4189-92. PubMed ID: 22578459
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
6. Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Kang KA; Piao MJ; Kim KC; Zheng J; Yao CW; Cha JW; Kim HS; Kim DH; Bae SC; Hyun JW
Int J Oncol; 2013 Dec; 43(6):1907-14. PubMed ID: 24100442
[TBL] [Abstract][Full Text] [Related]
7. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
Choi E; Lee C; Park JE; Seo JJ; Cho M; Kang JS; Kim HM; Park SK; Lee K; Han G
Bioorg Med Chem Lett; 2011 Feb; 21(4):1218-21. PubMed ID: 21256006
[TBL] [Abstract][Full Text] [Related]
8. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
10. Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
Kim HM; Hong SH; Kim MS; Lee CW; Kang JS; Lee K; Park SK; Han JW; Lee HY; Choi Y; Kwon HJ; Han G
Bioorg Med Chem Lett; 2007 Nov; 17(22):6234-8. PubMed ID: 17904843
[TBL] [Abstract][Full Text] [Related]
11. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
13. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
[TBL] [Abstract][Full Text] [Related]
15. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
16. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
Liu YM; Lee HY; Chen CH; Lee CH; Wang LT; Pan SL; Lai MJ; Yeh TK; Liou JP
Eur J Med Chem; 2015 Jan; 89():320-30. PubMed ID: 25462248
[TBL] [Abstract][Full Text] [Related]
17. Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
Taddei M; Cini E; Giannotti L; Giannini G; Battistuzzi G; Vignola D; Vesci L; Cabri W
Bioorg Med Chem Lett; 2014 Jan; 24(1):61-4. PubMed ID: 24345446
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
